Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jayashri Shembalkar

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
BMJ Case Reports|April 16, 2024
Eruptive xanthomasVikrant Saoji, Bhushan Madke, Jayashri Shembalkar, et al.
Therapeutic Advances in Endocrinology and Metabolism|November 21, 2025
Comparing the efficacy and safety of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency: a plain language summary of publicationRoy Gomez, Vaman Khadilkar, Jayashri Shembalkar, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|May 8, 2024
<i>Post hoc</i> subgroup analysis of Asian children with paediatric GHD from the global phase 3 efficacy and safety study of once-weekly somatrogon vs. once-daily somatropinRoy Gomez, Vaman Khadilkar, Jayashri Shembalkar, et al.
Indian Journal of Endocrinology and Metabolism|January 9, 2023
Clinical and Demographic Profile of Diabetic Patients from Central India - Results from Diabetes RegistryShailesh Pitale, Anagha Sahasrabuddhe, Pramod Gandhi, et al.
Drugs|March 13, 2020
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled TrialMala Dharmalingam, S R Aravind, Hemant Thacker, et al.
The Journal of the Association of Physicians of India|February 2, 2025
A Prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal OsteoporosisThomas Paul, Bhavuk Garg, Nitin Kapoor, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
BMJ Case Reports|April 16, 2024
Eruptive xanthomasVikrant Saoji, Bhushan Madke, Jayashri Shembalkar, et al.
Therapeutic Advances in Endocrinology and Metabolism|November 21, 2025
Comparing the efficacy and safety of weekly somatrogon with daily somatropin in Asian children living with growth hormone deficiency: a plain language summary of publicationRoy Gomez, Vaman Khadilkar, Jayashri Shembalkar, et al.
Journal of Pediatric Endocrinology & Metabolism : JPEM|May 8, 2024
<i>Post hoc</i> subgroup analysis of Asian children with paediatric GHD from the global phase 3 efficacy and safety study of once-weekly somatrogon vs. once-daily somatropinRoy Gomez, Vaman Khadilkar, Jayashri Shembalkar, et al.
Indian Journal of Endocrinology and Metabolism|January 9, 2023
Clinical and Demographic Profile of Diabetic Patients from Central India - Results from Diabetes RegistryShailesh Pitale, Anagha Sahasrabuddhe, Pramod Gandhi, et al.
Drugs|March 13, 2020
Efficacy and Safety of Remogliflozin Etabonate, a New Sodium Glucose Co-Transporter-2 Inhibitor, in Patients with Type 2 Diabetes Mellitus: A 24-Week, Randomized, Double-Blind, Active-Controlled TrialMala Dharmalingam, S R Aravind, Hemant Thacker, et al.
The Journal of the Association of Physicians of India|February 2, 2025
A Prospective, Active-controlled, Randomized, Double-blind, Multicenter, Phase III Study to Compare the Safety and Efficacy of Biosimilar Denosumab vs Reference Denosumab in the Treatment of Postmenopausal OsteoporosisThomas Paul, Bhavuk Garg, Nitin Kapoor, et al.
Pageof 1